Structure Therapeutics Newsroom

The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.

Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.

wallstreetcnNov 17 07:00 ET

Eli Lilly, Novo Nordisk Shares Slide as Trump Picks RFK Jr. for HHS Post

MarketWatchNov 15 14:25 ET

Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118

Moomoo NewsNov 15 08:31 ET · Ratings

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswireNov 15 08:30 ET

Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79

Moomoo NewsNov 14 08:35 ET · Ratings

Structure Therapeutics Reports Strong Q3 2024 Results

TipRanksNov 13 23:35 ET

Structure Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 22:32 ET · Announcements

Structure Therapeutics Expects Cash to Fund Operations Through at Least 2027

TipRanksNov 13 16:26 ET

Express News | Structure Therapeutics Inc - Topline Data From Access and Access II Studies Expected Q4 2025

ReutersNov 13 16:23 ET

Express News | Structure Therapeutics Q3 EPS $(0.20), Inline

BenzingaNov 13 16:19 ET

Express News | Structure Therapeutics Inc: Expects Current Cash, Cash Equivalents & Short-Term Investments to Fund Operations Through at Least 2027

ReutersNov 13 16:13 ET

Express News | Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

ReutersNov 13 16:05 ET

Express News | Structure Therapeutics Inc. Q3 Income From Operations USD -45.836 Million

ReutersNov 13 16:05 ET

Express News | Structure Therapeutics Inc. Q3 Net Income USD -33.977 Million

ReutersNov 13 16:05 ET

Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity

BenzingaNov 13 16:04 ET

Express News | Structure Therapeutics Announces First Patients Dosed in Phase 2B Access Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, Gsbr-1290, for Obesity

ReutersNov 13 16:01 ET

Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93

Moomoo NewsNov 5 07:35 ET · Ratings

Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TipRanksNov 5 06:58 ET · Ratings

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024

GlobeNewswireOct 31 08:30 ET

Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral

Seeking AlphaOct 21 14:52 ET